NASH and Fatty Liver in the era of COVID-19 

NASH & Fatty Liver Disease in the Time of COVID-19 for healthcare professionals featuring Dr. Mary Rinella, Northwestern Medicine, Dr. Michael Charlton, University of Chicago, and moderated by Dr. Rocky Yapp, Amita Health/Good Samaritan Hospital. CMEs available.
This was recorded on September 1, 2020.
Please remember to donate to the American Liver Foundation: liverfoundation.org/for-patie...
Chapters:
0:00 - Introductions
8:12 - Dr. Mary Rinella, Northwestern Medicine presenting General impact and Surveillance of Fatty Liver Patients During COVID-19
31:50 - Dr. Michael Charlton, University of Chicago presenting NASH Therapeutics in the Time of COVID
1:00:23 - Q&A
For more information about the American Liver Foundation, visit liverfoundation.org/for-patie...
If you've liked what you've seen on this video, then please consider clicking the red "Subscribe" button to be notified when new videos from the American Liver Foundation are posted. Click "Like" and "Share" this with your friends. Leave a comment below and we'll respond as soon as possible. Thank you.
*NAFLD has been newly renamed metabolic dysfunction-associated steatotic liver disease or MASLD. NASH has been newly renamed metabolic dysfunction associated steatohepatitis or MASH. Fatty liver disease has been newly renamed to steatotic liver disease or SLD. Learn more here: alf.social/SLD